Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard ...

Lung cancer leads global cancer mortality, and non-small-cell variants make up more than 80% of cases. Immune checkpoint inhibitors have transformed therapy yet help only 27–45% of recipients.

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is the current standard first-line therapy for patients with metastatic non–small cell lung cancer (NSCLC) ...

Radiation therapy is a precise, targeted treatment for lung cancer that can be used at every stage of the disease, according to Dr. Julianna Bronk during her presentation at the CURE Educated Patient® ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

One emergency room trip and several tests later, the 30-year Navy veteran was told to prepare for his toughest battle yet: stage 4 non-small-cell lung cancer, adenocarcinoma. "We weren't sure what was ...

In 2022, approximately 2.5 million lung cancer cases were diagnosed globally. Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide.

Pancreatic cancer spreads to liver or lung thanks to this protein. ScienceDaily. Retrieved June 11, 2025 from www.sciencedaily.com / releases / 2025 / 06 / 250603141156.htm.

In the United States, fewer than 16% of eligible patients get screened for lung cancer with specialized low-dose CT scans. That leaves a huge gap in detection, and a major opportunity.